Gan Lai Pharmaceutical's THRβ agonist phase I clinical trial in the United States achieved good top-line data

On September 8th, Gan Lai Pharmaceutical, a wholly-owned subsidiary of Gerry Pharmaceuticals, announced that the liver-targeted prodrug ASC41 oral tablet healthy subjects drug interactions and the pharmacokinetics of non-alcoholic fatty liver disease (NAFLD) patients PK (Phase I clinical trials in the United States) achieved good top-line data

The clinical study consists of two cohorts

Drug interaction data showed that there was no clinically significant difference in the exposure of the active metabolite ASC41-A with or without itraconazole or phenytoin

The study also showed that the pharmacokinetic characteristics of ASC41/ASC41-A were not significantly different between healthy subjects and NAFLD patients

In addition, the pharmacokinetic results of the US study are comparable to those of the ASC41 China Phase I study, indicating that the drug does not have significant pharmacokinetic differences between the Chinese and American populations

Note: The original text has been deleted